Sudden deaths in psychiatric patients

Journal of Clinical Psychiatry

Volumn 72, Issue 7, 2011, Pages 936-941

  Manu, Peter ^a,b   Kane, John M ^a,b   Correll, Christoph U ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; VENLAFAXINE;

ACUTE CORONARY SYNDROME; ADULT; ANXIETY DISORDER; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; COMMOTIO CORDIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG DEPENDENCE; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL HOSPITAL; MENTAL PATIENT; MOOD DISORDER; MYOCARDITIS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; RISK FACTOR; ROOT CAUSE ANALYSIS; SEPTIC SHOCK; STROKE; SUDDEN DEATH; UNITED STATES; UPPER RESPIRATORY TRACT OBSTRUCTION;

ACUTE CORONARY SYNDROME; ADULT; AGED; AIRWAY OBSTRUCTION; ANTIPSYCHOTIC AGENTS; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEATH, SUDDEN; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; INTRACRANIAL THROMBOSIS; MALE; MIDDLE AGED; NEW YORK CITY; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79960710828     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06244gry     Document Type: Article

References (27)

1. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235. doi:10.1056/NEJMoa080694 PubMed
2. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58(12):1161-1167. doi:10.101/archpsyc.58.12.161 PubMed (Pubitemid 33121508)
3. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325(7372):1070-1075. doi:10.136/bmj.325.7372.1070 PubMed
4. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62(11):1649-1671. doi:10.2165/03495- 2026210-06 PubMed (Pubitemid 34848372)
5. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22(1):39-43. doi:10.1097/HCO. 0b013e3280129eb PubMed (Pubitemid 44901054)
6. Lieberman JA, Merrill D, Parameswaran S, for the APA Council on Research; New York State Office of Mental Health. APA guidance on the use of antipsychotic drugs and cardiac sudden death.http://www.omh.ny.gov/omhweb/ advisories/adult-antipsychotic-use-attachement.html. Accessed January 27, 2011.
7. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on sudden cardiac death of the European Society of Cardiology. Eur Heart J. 2001;22(16):1374-1450. doi:10.1053/euhj.201.2824 PubMed (Pubitemid 32771346)
8. Every NR, Parsons L, Hlatky MA, et al. Use and accuracy of state death certificates for classification of sudden cardiac deaths in high-risk populations. Am Heart J. 1997;134(6):1129-1132. doi:10.1016/S02-8703(97)7035-8 PubMed (Pubitemid 28040204)
9. Iribarren C, Crow RS, Hannan PJ, et al. Validation of death certificate diagnosis of out-of-hospital sudden cardiac death. Am J Cardiol. 1998;82(1):50-53. doi:10.1016/S02-9149(98)0240-9 PubMed (Pubitemid 28322034)
10. Chugh SS, Reinier K, Teodorescu C, et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis. 2008;51(3):213-228. doi:10.1016/j.pcad.208.06.03 PubMed
11. Di Lenarda A, Secoli G, Perkan A, et al; The Heart Muscle Disease Study Group. Changing mortality in dilated cardiomyopathy. Br Heart J. 1994;72(suppl):S46-S51. doi:10.136/hrt.72.6-Supl.S46 PubMed
12. Shen WK, Edwards WD, Hammill SC, et al. Sudden unexpected non-traumatic death in 54 young adults: a 30-year population-based study. Am J Cardiol. 1995;76(3):148-152. doi:10.1016/S02-9149(9)8047-2 PubMed
13. Grundy SM. United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol. 2001;88(7B):23J-27J. doi:10.1016/S02-9149(01)01931-2 PubMed
14. Siscovick DS, Sotoodehnia N, Rea TD, et al. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. Rev Endocr Metab Disord. 2010;11(1):53-59. doi:10.107/s154-010-913-5 PubMed
15. Kucharska-Newton AM, Couper DJ, Pankow JS, et al. Diabetes and risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol. 2010;(47 Suppl 1):161-168. PubMed
16. Correll CU, Frederickson AM, Kane JM, et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006;67(4):575-583. doi:10.408/JCP. v67n0408 PubMed (Pubitemid 43764234)
17. Twaites BR, Wilton LV, Shakir SAW. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England. J Psychopharmacol. 2007;21(4):392-399. doi:10.17/02698107073257 PubMed (Pubitemid 47078926)
18. Martinez C, Assimes TL, Mines D, et al. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ. 2010;340:c249. doi:10.136/bmj.c249 PubMed
19. Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(1):CD006625. PubMed
20. Barnes TR, Paton C, Cavanagh M-R, et al; UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull. 2007;33(6): 1397-1403. doi:10.1093/schbul/sbm038 PubMed
21. Morrato EH, Newcomer JW, Kamat S, et al. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care. 2009;32(6):1037-1042. doi:10.237/dc08-1720 PubMed
22. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009;166(3):345-353. doi:10.176/api.ajp.208.08030383 PubMed
23. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry. 2010;67(1):17-24. doi:10.101/archgenpsychiatry.209.179 PubMed
24. Druss BG, Bradford WD, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry. 2001;58(6):565-572. doi:10.101/archpsyc.58.6.565 PubMed (Pubitemid 32523736)
25. Frye RL. Optimal care of patients with type 2 diabetes mellitus and coronary artery disease. Am J Med. 2003;115(suppl 8A):93S-98S. doi:10.1016/j.amjmed.203.09.015 PubMed
26. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1-3):15-22. doi:10.1016/j.schres.206.06.026 PubMed (Pubitemid 44234064)
27. Correll CU, Kane JM, Manu P. Identification of high-risk coronary heart disease patients receiving atypical antipsychotics: single low-density lipoprotein cholesterol threshold or complex national standard? J Clin Psychiatry. 2008;69(4):578-583.